Guardant Health (GH) stock hit a five-year high Thursday after key competitor Freenome unveiled study results for its colon cancer blood test.
The study met its goals
Freenome’s SimpleScreen test showed 80.4% sensitivity for detecting colorectal cancer. It also had 90% specificity for no findings on colonoscopy. Sensitivity measures a test’s ability to correctly identify those with disease.
Specificity rules… Related news Healthcare Stocks Rise To The Heart Of IBD’s Elite List Of Growth Names 7/02/2026 Healthcare stocks are attracting attention in a market broadening beyond AI-driven tech names, and now make up a big chunk… 7/02/2026 Healthcare stocks are attracting attention in a market broadening beyond